Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Triple Negative Breast Cancer (TNBC)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT02996825
What this trial is testing

Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer

Who this might be right for
Recurrent Breast CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian Carcinoma+3 more
City of Hope Medical Center 44
Testing effectiveness (Phase 2)Active Not RecruitingNCT03449108
What this trial is testing

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Who this might be right for
Bone SarcomaDedifferentiated ChondrosarcomaGiant Cell Tumor of Bone+13 more
M.D. Anderson Cancer Center 30
Large-scale testing (Phase 3)Looking for participantsNCT05909332
What this trial is testing

Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)

Who this might be right for
Breast CancerTriple Negative Breast Cancer
Fudan University 764
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07244874
What this trial is testing

Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC

Who this might be right for
TNBC - Triple-Negative Breast CancerPD-L1 Positive
Tianjin Medical University Cancer Institute and Hospital 41
Large-scale testing (Phase 3)UnknownNCT05954442
What this trial is testing

Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype

Who this might be right for
Triple Negative Breast CancerMetastatic Breast CancerMutation
Fudan University 203
Testing effectiveness (Phase 2)Looking for participantsNCT06636981
What this trial is testing

All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II Trial

Who this might be right for
Triple Negative Breast Cancer (TNBC)
Fudan University 129
Large-scale testing (Phase 3)UnknownNCT04907344
What this trial is testing

Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Who this might be right for
Triple Negative Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 420
Testing effectiveness (Phase 2)Looking for participantsNCT07208149
What this trial is testing

MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)

Who this might be right for
Triple-Negative Breast Cancer (TNBC)
Shenzhen Majory Biotechnology Co., Ltd. 42
Large-scale testing (Phase 3)Active Not RecruitingNCT05629585
What this trial is testing

Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

Who this might be right for
Breast Cancer
AstraZeneca 1,174
Testing effectiveness (Phase 2)Study completedNCT01997333
What this trial is testing

Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer

Who this might be right for
Metastatic gpNMB Over-expressing Triple Negative Breast Cancer
Celldex Therapeutics 327
Large-scale testing (Phase 3)Looking for participantsNCT05760378
What this trial is testing

Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.

Who this might be right for
Triple-Negative Breast Cancer
Fudan University 223
Testing effectiveness (Phase 2)Study completedNCT02938442
What this trial is testing

Vaccination of Triple Negative Breast Cancer Patients

Who this might be right for
Triple Negative Breast CancerBreast Neoplasms
University of Arkansas 16
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07161791
What this trial is testing

Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer

Who this might be right for
Breast CancerTriple Negative Breast Cancer (TNBC)
Harbin Medical University 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT05933265
What this trial is testing

Study of LP-184 in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorMetastatic Solid TumorGBM+4 more
Lantern Pharma Inc. 64
Early research (Phase 1)Ended earlyNCT06878248
What this trial is testing

Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer MetastaticLocally Advanced Breast Cancer (LABC)Malignant Neoplasm of Breast+3 more
Calibr, a division of Scripps Research 10
Not applicableNot Yet RecruitingNCT07491822
What this trial is testing

A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer

Who this might be right for
TNBC
Tianjin Medical University Cancer Institute and Hospital 43
Not applicableUnknownNCT02464774
What this trial is testing

Breast-Conserving Therapy in Patients With Triple-Negative Breast Cancer

Who this might be right for
Breast Cancer
Xiaoming Xie 464
Testing effectiveness (Phase 2)Looking for participantsNCT06358573
What this trial is testing

Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK

Who this might be right for
Triple-negative Breast CancerTNBC - Triple-Negative Breast Cancer
Swiss Cancer Institute 61
Testing effectiveness (Phase 2)Study completedNCT07827079
What this trial is testing

Tislelizumab Combined With TAC Regimen as Neoadjuvant Therapy for TNBC

Who this might be right for
Breast Cancer (Triple Negative Breast Cancer (TNBC))Chemeotherapy
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 36
Testing effectiveness (Phase 2)Ended earlyNCT06067061
What this trial is testing

"neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer

Who this might be right for
Triple Negative Breast Neoplasms
Institut Curie 2
Next Page